New drug AMG 256 tested in patients with hard-to-treat cancers

NCT ID NCT04362748

Completed Disease control Sponsor: Amgen Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-phase study tested a new drug called AMG 256 in 34 adults with advanced solid tumors that could not be cured by standard treatments. The main goals were to check the drug's safety and find the best dose for future studies. Researchers monitored side effects and how the drug moved through the body.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED SOLID TUMORS

Contacts and locations

Locations

Chris OBrien Lifehouse

Camperdown, New South Wales, 2050, Australia
City of Hope National Medical Center

Duarte, California, 91010, United States
Cliniques Universitaires Saint Luc

Brussels, 1200, Belgium
Hospital Clinic i Provincial de Barcelona

Barcelona, Catalonia, 08036, Spain
Hospital Universitari Vall d Hebron

Barcelona, Catalonia, 08035, Spain
Indiana University

Indianapolis, Indiana, 46202, United States
Monash Medical Centre

Clayton, Victoria, 3168, Australia
St Vincents Hospital Sydney

Darlinghurst, New South Wales, 2010, Australia
Universitair Ziekenhuis Gent

Ghent, 9000, Belgium
University of Texas MD Anderson Cancer Center

Houston, Texas, 77030, United States
Washington University

St Louis, Missouri, 63110, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.